Proprietary Micelle Drug Formulation
Our patented drug delivery technology, developed in partnership with the University of Toronto, represents a significant advancement in the field of natural compound therapeutics. Central to this technology is our patented emulsion-based micellisation process, that can be specifically tailored for different molecules.
This approach can be particularly transformative for compounds like CBD, which traditionally suffer from poor bioavailability (ranging between 6%-10%). By employing our cutting-edge micelle formulations, we can substantially enhance both the bioavailability and stability of hydrophobic natural compounds, thereby amplifying their therapeutic efficacy.
Moreover, the manufacturing of our micelle formulation is straightforward and cost-effective, aligning with our commitment to accessible healthcare solutions. This technology is not just a step forward in improving the effectiveness of natural compounds like CBD; it's a leap towards unlocking their full therapeutic potential.
- Superior Bioavailability
- Better therapeutic potential and lower Cost of Goods Sold (COGS)
- Enhanced Lymphatic Absorption
- Minimized Variability in Blood Plasma Levels
- Straightforward and cost-effective manufacturing
- Desirable Patient Usability
As a hydrophobic molecule, CBD is sequestered in the oil core of the micelle. The hydrophobic chains of the surfactant arrange themselves towards the oil core, and hydrophilic head groups point towards the outside, keeping water out of the micelle.